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ABSTRACT 
The tumour heterogeneity and interindividual variability is a major problem when treating 
cancer as every patient responds in a different way to the current drug therapies. 3D printing is 
a tool that can hamper the issues faced in cancer patients allowing for individualisation of 
treatment by the production of in vitro models with micro-environments mimicking more 
closely real cancer conditions facilitating complex therapies. Further improvements are 
required, for example the development of  biocompatible bioinks or  need for vascularisation. 
The journey from bench to bedside is challenging  from the regulatory point of view where the 
establishment of manufacturing guidelines, quality systems and safety of use and 
administration of personalised medicines remains unclear. This review will provide an insight 
in the major applications of 3D printing in cancer both in the development of in vitro cancer 
models as well as personalised medicines for cancer patients focused on hydrogels and 
therapeutic implants. 
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PERSONALISED THERAPIES AND 3D PRINTING 
Cancer is the second leading cause of death in the world, being responsible for one of every six 
deaths that occur annually [1]. Unfortunately, new cases are predicted to increase 
approximately by 70% in the next 20 years [1]. Thus, it is critical to develop more sensitive 
technologies for early diagnosis and targeted therapies that are more active and with less 
adverse effects [2].  
Tumour heterogeneity and interindividual variability is a major problem when treating cancer 
as every patient responds in a different way to current drug therapies. Dose adjustments are 
frequently based on empirical methods leading to higher chance of undesirable side effects. 
Conventional drug manufacturing, in order to maintain the costs low, does not allow for 
tayloring the dose to individual patients leaving a clear unmet need.   
Drug manufacturing has moved forward from traditional dosage forms to targeted 
biopharmaceuticals and nanomedicines that have an increased specificity and reduced toxicity. 
Novel manufacturing technologies based on Rapid Prototyping, also known as 3D printing or 
additive manufacturing, involve the fabrication of 3D physical models prepared based on 
computer-aided design, are proposed towards the manufacture of personalised therapies [4]. 
Rapid prototyping was first introduced in 1980 by the Japanese Dr. Hideo Kodama that filed a 
patent for Rapid prototyping technology, which was denied by authorities as he missed the one-
year deadline to file the full patent requirements. Four years later, the American Charles Chuck 
Hull filed the first patent on stereolitography [5] and in the early 90s, at the Massachuset 
Institute of Technology, Sachs et al. filed a patent on another 3D technology known as inkjet 
printing where a binder solution was deposited onto a powder material bed [6]. Nevertheless, 
several decades have passed until these techniques were applied in the production of medicines. 
Aprecia Pharmaceuticals in the 2016 was the first company to get approval by the FDA and 
launch to the market the first 3D printed medicine, Spritam®, containing levetiracetam 
indicated in epileptic attacks. This medicines is produced by using a Zip Dose Technology 
(inkjet printing) where the layers are deposited one on top of the other resulting in a 3D highly 
porous  tablet with a very fast disintegration [7]. In 2012, Scott Crump filed a patent on another 
well-extended 3D printing technology, currently known as Fused Deposition Modeling [8], 
which has been applied latter on in the development of solid dosage pharmaceutical forms. 
This technique is based on printing using drug-excipient filaments produced by hot melt 
extrusion that are fed into a extruder nozzle that heats the filaments and deposits the semi-solid 
material onto a platform layer by layer till harden into a 3D object [9].  
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Nowadays, 3D printing is a tool that can hamper the issues faced in cancer patients allowing 
for individualisation of treatment by the production of in vitro models with micro-environments 
mimicking more closely real cancer conditions facilitating complex therapies. This review will 
provide an insight in the major applications of 3D printing in cancer both in the development 
of in vitro cancer models as well as 3D printed personalised medicines for cancer patients 
focused on hydrogels and therapeutic implants.  
3D BIOPRINTING OF IN VITRO CANCER MODELS  
Executive summary 
 There are several types of 3D printing techniques but not all of them are suitable for 
bioprinting as they should be relatively mild and cell friendly.  
 Bioinks have to possess certain properties in order to ensure the quality of the 3D 
printed scaffolds such as: printability, functionality, and mechanical strength. 
 The evolution from simple 2D to complex 3D bioprinted models allows to address 
many of the challenges associated with cancer models such as disease progression, 
metastasis, spatio-temporally evolving cell-matrix interactions, hypoxic cores, leaky 
unorganised vasculature and presence of host signaling molecules. 
Bioprinting challenges 
3D bioprinting can accurately build highly complex architectures and tissue models in a layer-
by-layer manner and hence, advances on this field are key to mimic what is happening in real 
tissues [10]. When developing in vitro cancer models, highly porous scaffold materials as used 
as a template to induce the growth and differentation of cells creating ideal microenvironments 
mimicking the in vivo conditions for drug testing. When printing tumour organoids, several 
issues have to be considered such as vascularization, innervation and safety of biomaterials 
used before their used in drug screening and development [11]. Conventional techniques such 
as injection molding, electrospinning and porogen-leaching have a limited control over the cell 
distribution within the scaffold, its final architecture, pore size and composition [12]. Herein, 
it is a necessity to be able to reproduce the complexity of alive tissues and in order to do that, 
a highly precision in the scaffold construction is required. A major limitation in this field is to 
design suitable bioinks that allow printing of living cells. Therefore, printing at elevated 
temperatures is not an option as cells can be easily damaged. However, most polymers utilised 
in 3D printing require the use of high temperatures or solvents in order to either melt or dissolve 
the polymer such as polycaprolactone or polylactic acid [13]. The development of suitable 
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bioinks and the use of an appropriate bioprinting method are key to ensure the success of 3D 
bioprinting. 
3D Bioprinting methods 
There are several types of 3D printing techniques but not all of them are suitable for bioprinting 
as they should be relatively mild and cell friendly. Droplet-based, extrusion-based and laser-
based are the most commonly used methods. The two most typical droplet-based methods are: 
continuous inkjet printing (CIJ) and drop-on-demand (DOD). CIJ consists on a high pressure 
pump that directs the liquid ink towards an orifice (50-80 µm) creating a continuous ink flow. 
The liquid ink is broken down into small drops of a specific size (usually between 10-50 µm 
equivalent 1 to 70 pL) due to the action of the piezoelectric crystal. Droplets are 
electrostatically charged and hence, they are directly deposited on the platform due to the 
electrostatic field that is generated (Fig. 1). The DOD printing method employs multiple heads 
and uses two types of translators (piezoelectric crystal or thermal head). The thermal head can 
reach temperatures of up to 300°C, which can induce the degradation of bioactive compounds 
and cells. For this reason, CIJ methods are more suitable for bioprinting [4].  
Regarding the extrusion-based methods, the ink is passed through a nozzle that originates layer 
by layer the 3D structure. Extrusion-based methods can be divided in two different types of 
printing depending on if the ink has to be melted (in the case of Fused Deposition Modeling, 
FDM) or not (Pressure-Assisted Microsyringes, PAM). FDM allows to produce complex 
scaffolds with high mechanical strength; however this technique is not suitable for bioprinting 
as requires melting of the materials that can provoke cell degradation. The fundamental 
principle of FDM consists on filaments that are arranged in rolls in a way that go through an 
extruder nozzle whose temperature is above the melting temperature of the material which 
melts and deposits, layer by layer in the form of very fine filaments that pretty fast solidify 
(Fig. 2). This technique is broadly used in the manufacturing of solid dosage forms due to its 
ability to produce complex geometries with high quality and at good speed but it is less suitable 
for bioprinting [3,14]. In contrast, PAM technology is a good option for bioprinting in which a 
viscous and semi-solid material is deposited layer by layer by means of a pressurised air piston 
and a syringe extruder (Fig. 3). The major advantage of this technique is the fact that can work 
at room temperature using aqueous based materials with a continuous flow. In order to print 
accurately complex scaffolds, it is necessary to investigate in advance the viscosity, 
viscoelastic properties and apparent elastic limits of the printed materials as they are key 
elements to ensure the adequate deposition of the bioinks on the substrate [15]. 
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Laser-based printing methods are characterised by the use of an ultraviolet light beam in the 
form of a laser that transfers the energy into a liquid photopolymerizable resin. In order for the 
photopolymerization to occur, radicals have to be released after the interaction between the 
photoinitiator and the UV light resulting in solidification of the material. When a layer 
solidifies, the building platform goes down so a new layer of liquid resin will receive the laser 
beam and will solidify leading to the final tridimensional geometry (Fig. 4). The major 
advantages of this technique are its high resolution as well as the low heating required during 
the printing. Hence, this technique could potentially be employed for bioprinting as long as a 
cell-laden propolymer formulation is used and the photocuring process takes places in a cell 
friendly conditions [16]. Laser-induced forward transfer can also be used in bioprinting. In this 
case, ink solution is deposited on a glass slide which is coated with a laser absorption layer 
such as a metal oxide towards which is directed the laser, creating a local pressure to eject the 
ink layer to the substrate [10,17]. However, the lack of GRASS (Generally Recognised as Safe) 
excipients is one of the limitations of these techniques. 
Bioink design for 3D bioprinting 
Bioinks have to possess certain properties in order to ensure the quality of the 3D printed 
scaffolds. These properties can be summarised basically in three: printability, functionality, 
and mechanical strength. Printability involves the capacity of the ink to be fed into the 3D 
printer and to be processed resulting in a scaffold with enough mechanical strength to hold the 
shape, keep the functionality and ensure living cells after printing [18]. One of the key 
parameters that affect the printing process is the viscosity of the bioink. In this sense, inks with 
high viscosity hold the shape of the scaffold for longer times post-printing; however, higher 
pressures are required during the printing process which maybe not be possible in certain cases 
limiting the achievable print size [19]. For this reason, inks with shear-thinning characteristic 
are better for printing. Overall, lower viscosities are recommended for droplet-based printing 
with values close to 10 mPa⋅s, while higher viscosity inks can be used in laser-based printing 
(ranging from 1 to 300 mPa⋅s) or even higher in PAM (ranging from 30 to 6 x 107 mPa⋅s) 
[20,21].  Also, bioinks should not contain substances that induce inflammation or cytotoxicity. 
They should be biocompatible and ensure high cell viability and keep cellular behavior such 
as adhesion, differentation and migration [10]. Pressure induce differentation in cells. 
Overall, the most common bioinks are cell-laden hydrogels, decellularised extracellular matrix-
based solution and cell suspensions [10]. The major advantage of the cell-laden hydrogels is 
their ability to mimic the cellular environment. Hydrogels can be constructed using natural 
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compounds (such as collagen, gelatin, fibrin, hyaluronic acid, alginate, agarose), synthetic 
polymers (like pluronic, poly-ethylene glycol, peptide amphiphiles [22]) or a mixture of both 
of them in order to combine their properties. For instance, natural compounds resemble better 
the extracellular matrix with inherent bioactivity whereas synthetic hydrogels even though do 
not promote cellular function unless made by bioactive peptide amphiphiles, possess tunable 
mechanical properties usually based on cross-linking reactions leading to self-supporting 
structures [23]. The decellularised extracellular matrix bioinks are more costly as they are 
obtained after removing the cells and preserving the matrix and combining it with a carrier 
polymer to adjust some parameters such as viscosity and solubility, but have the advantage of 
exhibiting better printability capacity while keeping their inherent bioactivity [24]. Cell 
suspension inks are also a good alternative for bioprinting. They are based on cell aggregates 
in suspension in the form of mono- or multicellular spheroids which undergoes a 
transformation after bioprinting due to cell-cell interactions. The presence of a temporary 
support layer can be required in certain cases [25]. 
In vitro cancer models 
In vitro cancer models have relied on last decades mostly on 2D mono-cell cultures and animal 
models. However, 2D models have poor translational success as they have many limitations in 
mimicking the tumor environment in humans. The evolution from simple 2D to complex 3D 
bioprinted models allows to address many of the challenges associated with cancer models 
such as disease progression, metastasis, spatio-temporally evolving cell-matrix interactions, 
hypoxic cores, leaky unorganised vasculature and presence of host signaling molecules [26]. 
Even though, there is no a single 3D bioprinted model able to reproduce all cancer features as 
above described, different approaches have been attempted in order to obtain a model that 
imitates as close as possible what really occurs within tumors (Table 1) [27]. 
Bioprinting has been successfully employed in the development of tumor spheroids which 
resemble the cellular heterogeneity of solid in vivo tumors characterised by containing cells in 
different proliferative and metabolic states with an external proliferating zone, an internal 
quiescent zone caused by limited distribution of oxygen, nutrients and metabolites and a 
necrotic core [28]. These models are very useful for drug testing and high-throughput screening 
of therapeutics. There are several examples of 3D bioprinted spheroids using MCF-7 and 
BT474 breast cancer cells [29,30], HeLa cells for cervical tumor [31] and stem SU3 cell line 
for glioma [32]. The bioink composition to construct the scaffold varied from PEG-
dimethacrylate, PEG-diacrylate to gelatin-alginate-fibrinogen (Fig. 5) [26,33]. Overall, 3D 
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spheroid models have demonstrated that are able to reproduce typical factor and enzyme 
secretion according to the type of tumor, like vascular endothelial growth factor and matrix-
degrading enzymes, but also have exhibited significantly higher resistance to drugs compared 
to 2D models mimicking closer the in vivo environment.  
Apart from developing microtumor environments through 3D bioprinted spheroids, the study 
of cell-cell communication is also key to understand the regulatory pathways controlling the 
progression of the disease, adhesion, migration and metastatic behavior. For example, cancer 
cell interaction with immune cells like macrophages through paracrine communication is 
known to play a crucial role in tumor cell extravasation and hence, metastasis development 
[34]. 3D bioprinting has been successful in biomimeting vessel-like microenvironment 
containing macrophages in the core and MDA-MB-231 breast cancer cells in the sheath using 
peptide conjugated alginate fibers as support [35]. Another model to study the disease 
progression and the regulatory feedback mechanisms was based on a human ovarian cancer 
cells (OVCAR-5) co-cultured with normal fibroblasts overlaid on a MatrigelTM (a gelatinous 
protein mixture secreted by Engelbreth-Holm-Swarm mouse sarcoma cells) which 
spontaneously formed a multicellular acini. The acinar growth kinetics recapitulate features of 
ovarian cancer micronodules in vivo [36]. 
Also, several attempts have been performed to reproduce cancer cell migration behavior and 
hence, metastasis. For example, laser-based printers have been able to reproduce artificial bone 
microenvironment combining MDA-MB-231 breast cancer cells co-cultured with human fetal 
osteoblasts forming multi-cellular spheroids with hydrxyapatite nanoparticles, PEG and PEG-
diacrylate. This biomimetic model showed the migration capacity of cancer cells within bone-
like structures [37]. Stereolithography has also been employed to bioprint breast cancer cells 
(BrCa) co-cultured with bone stromal cells (fetal osteoblasts or bone marrow mesenchymal 
stem cells) encapsulated in gelatin methacyrlate hydrogel with nanocyrstalline hydroxyapatite. 
The 3D culture exhibited an increased vascular endothelial growth factor secretion compared 
to monocultured BrCa cell models leading to an enhanced migration of BrCa cells into the 
stromal cell-laden bioprinted matrix [38].  
Overall in vitro cancer models based on 3D bioprinting have evolved with great sophistication 
being capable of recapitulating the extremely complex and heterogeneous cancer 
microenviroment. However, further improvements are required like for example the need for 
vascularisation, innervation, financial cost and safety of bioinks used for the construct. [11].  A 
promising strategy to overcome these challenges is the fabrication of 3D printed organ-on-a-
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chip which allows the creation of micro-organs with heterogeneity, cellular arrangement, 
tissue-specific functions and cyclic movement within a microfluidic device whose construction 
can be easily automated for massive production and hence, reduced cost [39,40]. Further 
direction indicates that the hybridization of different types of bioprinting technologies will 
enhance the features of the in vitro cancer models based on the integration of extrusion-based 
units to print the polymeric scaffolds along with pressure-assisted microsyringes able to deposit 
different bioinks of interest [27,41]. 
  
3D PRINTING OF PERSONALISED CANCER TREATMENTS 
Executive summary: 
 3D printing can revolutionize cancer treatments by printing of personalised hydrogels, 
therapeutic implants and breast prostheses. 
 3D printed hydrogels are considered to be the next generation of hydrogels able not 
only of facilitating physical support for cells, but also promoting cell proliferation, cell 
differentiation as well as controlled released of therapeutic agents and cell-regulating 
factors. 
 3D printed therapeutic implants using different types of materials like metals and 
polymers have revolutionised the personalised medicine allowing a great flexibility in 
implant design to obtain a wide range of shapes and, a much better fit than conventional 
implants leading to greater results in patient health care. 
 Using 3D printed flexible breast molds is a simple and inexpensive solution owing to 
its flexible nature which allows the de-epithelialized DIEP flap placed in the mold 
changes into a shape symmetrical to the contralateral breast with only minor 
adjustments. 
Extensive work has been performed in the area of 3D printed polypills where more than one 
active ingredient is combined within a single dosage form. However, many polypills are 
targeting polymedicated patients with hypertension, diabetes and cholesterol and for this reason 
this review will focus on 3D printed hydrogels and therapeutic implants for cancer therapies. 
3D printed hydrogels for controlled drug release 
Hydrogels are based on polymeric networks consisting on hydrophilic macromonomers able 
to: (i) retain large amounts of water which makes them biocompatible with most soft biological 
tissues, (ii) minimise inflammatory reactions of the surrounding cells and (iii) construct 
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scaffolds due to good mechanical properties as well as facilitating drug encapsulation [42]. In 
order that hydrogel is formed, it is required to cross link the macromonomers either by physical 
noncovalent interactions or chemically covalent bonds or a mixture of both. In situ forming 
hydrogels are preferred over preformed hydrogels in order to avoid surgical interventions and 
also because drugs and other biological components can be incorporated by simple mixing with 
the precursor polymer solution. Upon injection, the initial fluidic nature of the precursor 
solution ensures proper shape adaptation within the cavity where it is administered and then 
gelation takes place under physiological conditions increasing the viscosity and ensuring 
controlled drug release [43].  
Amongst all different types of hydrogels, those denominated “smart” or “stimuli response 
hydrogels” have gained in popularity as they are able to change their volume (swell or shrink), 
degrade, release their drug cargo or exhibit a sol-gel phase transition in response to 
environmental stimuli like pH, pressure, light, ionic strength, temperature and concentration of 
specific biomolecules such as enzymes [44].  
3D printed hydrogels are considered to be the next generation of hydrogels able not only of 
facilitating physical support for cells, but also promoting cell proliferation, cell differentiation 
as well as controlled released of therapeutic agents and cell-regulating factors (Table 2). For 
example, poloxamer-based hydrogels with a solid-disk shape (12 x 1 mm) containing paclitaxel 
and rapamycin have been successfully 3D printed using an extrusion-based method achieving 
a 99% encapsulation efficiency. Disks absorbed water and swelled up by 2-fold in one hour 
maintaining controlled drug release over 24 h. Upon intraperitoneal implantation of a single 
disk carrying paclitaxel/rapamycin at 20/20 mg/kg in ES-2-luc human ovarian cancer-bearing 
xenograft mice, tumor burden decreased substantially from 100 to 30% one day post-surgery 
and mean survival was increased from 20 to 30 days [45].  
Laser-based printing methods (SLA) have also been successful in 3D printing of drug-loaded 
hydrogels. A 10% w/w ibuprofen-loaded hydrogels of cross-linked polyethylene glycol 
diacrylate containing up to 30% water were printed using a Formlabs 1+ SLA printer. Ibuprofen 
release rate was controlled based on the amount of water. Hence, the larger the water content, 
the higher the dissolution rate of the drug [46]. The same principle can be applied for cytostatic 
drugs.  As a proof of concept, stereolithography has been also utilised for 3D printing of self-
assembling thermoresponsive nanoemulsions into hierarchical mesostructured hydrogels [47]. 
Nanoemulsions are being investigating widely for potential application in cancer therapy as 
they can solubilise and target poorly soluble drugs [48].  However, to print a nanoemulsion-
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based ink with rheological and photoreactive properties satisfying the requirements of SLA 
printers is challenging. Hsiao et al, have developed a thermoresponsive ink consisting of 
poly(dimethyl siloxane) droplets suspended in an aqueous phase with a surfactant, sodium 
dodecyl sulphate, and a crosslinker, poly(ethylene glycol) dimethacrylate (PEGDMA). Control 
of the hydrogel microstructured was achieved due to the fast structural recovery of the 
nanomeulsion after large strain rate yielding along with a shear thinning behaviour that allows 
the ink to conform to the build platform of the printer. The PEGDMA molecules possess two 
main functions in the nanoemulsion-based ink, on one hand, they induce colloidal gelation 
which can be tuned depending on the temperature conditions and on the other hand, provide 
photochemically cross-linked hierarchical mesostructured hydrogels [47].  
Hydrogels with nanoscopic dimensions, known as nanogels, have properties similar to 
hydrogels, except to the fact that  nanogels can reach areas of the body with difficult access, 
being proficiently internalised by the target cells, reducing accumulation in non-target tissues 
and hence toxicity, being this the reason why they are becoming major contenders in the 
intracellular administration of chemotherapy drugs [49]. 3D printed nanogels have been used 
to be implanted in postoperative tumor cavities with the ability to release DNA nanocomplexes 
to eliminate residual glioma cells. The nanogel was constructed by laser-based printing 
technology using a gelatin methacrylamide scaffold incorporating DNA nanocomplexes which 
were composed of pVSVMP (a plasmid DNA encoding matrix protein of the vesicular 
stomatitis virus able to eradicate cancer cells after transfection and induce anticancer immunity 
response) and degradable heparin-polyehterimide nanogel particles [50]. To improve the 
transfection efficiency of particles, Pluronic F127 was also incorporated to the DNA 
complexes. Insertion of the nanogels into the glioblastoma resection cavity delayed tumour 
recurrence and significantly prolonged the overall survival in mice [50].  
3D printed therapeutic implants 
3D printed therapeutic implants using different types of materials like metals and polymers 
have revolutionised the personalised medicine allowing a great flexibility in implant design to 
obtain a wide range of shapes like screws, joints, and flat substrates and, a much better fit than 
conventional implants leading to greater results in patient health care [51].  
3D metal printing has been used successfully in manufacturing implants mainly for dental 
prosthesis and bone fractures [52]. Actually, fracture is one of the most common complications 
of bone cancer caused by a primary cancer starting in the bone or a secondary cancer 
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consequence of metastasis of cancer cells localised at other body sites. Bone cancer is mostly 
treated with parenteral administration of chemotherapeutics. High drug doses are necessary in 
order to achieve effective concentration at the bone site leading to high toxicity in the rest of 
the body and resulting in therapeutic failure in many cases [53]. One alternative strategy to 
hamper these issues is to utilise drug-loading bone implants able to release the 
chemotherapeutic drug directly at the affected site and reducing toxic concentrations in the rest 
of the body.  
Using a 3D metal printer (selective laser melting), titanium implants loaded with two types of 
anticancer drugs, doxorubicin and apoptosis-inducing ligand have been successfully prepared 
for the treatment of bone cancers [54]. The 3D-printed titanium wafers were manufactured by 
forming a layer of powder material that was selectively melted using a laser (Fig. 6). The 
process was repeated till the desired thickness of the implant was achieved. The implant was 
electrochemically anodized in order to generate an anodic layer featuring unique microparticles 
and nanosurface (consisting of vertically aligned nanotubes) topography to enhance 
biointegration. Doxorubicin and apoptosis-inducing ligand were loaded at 188 and 25 µg/cm2 
respectively by depositing a solution containing both drugs onto the surface of the 3D wafers 
and using vacuum forces to remove potential air gaps inside the nanotubes. Drug release 
occurred in two phases: an initial fast release within 6 h (40 and 70% of the chemotherapeutics 
was released respectively) followed by a slow release phase of 16 days for doxorubicin and 4 
days for the apoptosis-inducing ligand. The drug loaded therapeutic implant showed also strong 
in vitro anticancer efficacy against cancer cells (MDA-MB-231-TXSA)[54].  
Magnetic hyperthermia can be also used as potential treatment in cancer taking into account 
that induced hyperthermia (raising the temperature up to 45 °C) can cause tumour cell death 
[55]. Implantable anticancer magnetocaloric polycaprolactone (PCL)/ Fe3O4 nanoparticulated 
mats have been created using electrohydrodynamic jet (E-Jet) 3D printing technology [56]. 
When subjected to an alternating magnetic field due to the conversion of magnetic energy to 
heat induced by the external magnetism, the temperature of the magnetic particles raises 
leading preferentially to death of cancer cells over non-cancer cells [57].  
E-Jet printing consists on the printing of a liquid solution driven by an electric field. Due to the 
exposure to the electric field, mobile ions in a polarizable liquid accumulate at the liquid 
surface. The coulombic repulsion of the ions makes the meniscus of the liquid located at the 
nozzle of the printer deforms into a conical shape (known as Taylor cone). A drop of fluid is 
emitted from the apex of the nozzle towards the substrate when the electric field exceeds a 
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critical limit and hence, the stress from the surface charge repulsion at the cone apex exceeds 
the surface tension of the liquid [58]. A 7% (w/v) solution of PCL in solvents (DMF and DCM) 
was mixed with Fe3O4 magnetic starch nanoparticles producing composite solutions that were 
E-jet printed resulting in PCL/Fe3O4 mats [56]. PCL was employed due to its optimal 
biocompatible and biological stability properties which was combined with the anticancer 
magnetocaloric properties of the Fe3O4 nanoparticles. The advantage of 3D printing the mats 
is that significantly improves their specific surface area enhancing the contact with the cancer 
cells and then the efficacy of the therapy. The mats could be potentially placed after surgery in 
the vicinity of tumours avoiding frequent intravenous administration of anticancer drugs. In 
vivo experiments (based on studying the efficacy of the mats after implantation on tumour 
bearing mice) showed significantly tumour growth inhibition as well as prolongation of 
survival time after 4 weeks of treatment consisting of the application of external alternating 
magnetic fields over 45 min every other day [56]. 
3D printed models in breast reconstruction 
Breast cancer remains to be one of the most malignant diseases in women. The plastic surgery 
community has investigated which methods for breast reconstruction after mastectomy are the 
best leading to the least donor-site morbidity. The autologous DIEP (Deep Inferior Epigastric 
Perforator) flap reconstruction is one of the first choice methods, where the skin and abdominal 
fat along with the artery and inferior epigastric vein is extracted and transplanted to the same 
patient in the breast area. Although this technique of reconstruction tends to imitate quite well 
the form and the roundness of the original chest, still are required new methods of aesthetically 
progress [59,60]. 
The complexity that surgeons face when designing a breast for a specific patient with its form 
and its own projection, from a flap, can be facilitated using extrusion-based 3D printers like 
Fuse Deposition Modeling printer (FDM). Several reports have indicated that 3D printed 
personalised prostheses provide superior esthetics compared to the traditional wax-based 
handcrafted ones [61]. It is necessary to scan both the region of the affected breast and the not 
damaged one. The mirror image of the undamaged breast superimposed in the affected region 
can be printed three-dimensionally to be used both in the preoperative planning and 
intraoperative development.  
3D surface imaging (eg. MRI, CT-scan) gives reliable estimates of the required tissue volume, 
which is especially useful when a large volume of tissue is required to reconstruct a 
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symmetrical breast. Otherwise, flap type is merely subjective and underestimation of tissue 
volume would lead to an insufficient breast volume. Also, shaping flat adipocutaneous tissue 
into a rigid 3D mold can be challenging. Using 3D printed flexible breast molds is a simple 
and inexpensive solution owing to its flexible nature which allows the de-epithelialized DIEP 
flap placed in the mold changes into a shape symmetrical to the contralateral breast with only 
minor adjustments [60,62,63] (Fig. 2). 
The fabrication of 3D printable smart materials has resulted in four-dimensional printing that 
basically is the combination of 3D printing and time. 4D printing allows a printed object to be 
programmed to carry out shape change while adapting to its surroundings (known shape 
memory effect) upon certain stimuli such as temperature [64]. Last year, this 4D printing 
technology was successfully used in China to reconstruct a breast implant for cancer patient. 
The implant changed over time and patient´s fibrous tissue grew into the implant until 
eventually replaced it altogether [65]. 
 
Future perspectives and concluding remarks 
3D printing has become a potential tool when developing personalised treatments for cancer 
patients as well as more accurate in vitro tumor models. Overall, 3D printing offers numerous 
advantages such as increasing of accuracy when imitating physiological processes and tumor 
environment linked to much higher repeatability and reproducibility which can be translated in 
more effective anticancer drugs. 3D printed of personalised medicines such as hydrogels and 
implants loaded with cytostatic drugs are revolutionizing cancer treatments targeting tumor 
cells in a much specific way increasing efficacy and reducing the toxicity derived from a broad 
biodistribution in the body. However, the journey from bench to bedside is challenging 
especially from the regulatory point of view where the establishment of manufacturing 
guidelines, laws, quality systems and safety of use and administration of personalised 
medicines remains unclear.  
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Table 1.  3D printing of in vitro cancer models. Key: CIJ, continuous inkjet printing, CAF, cancer-associated fibroblast; PAM, pressure-
assisted microsyringes. 
 
 
 
 
 
 
Model Aim 
Bioink 
Type of printer REF. 
Cell (tumor type) Matrix 
Tumor spheroids 
To mimic in vivo 
tumor 
microenvironment, 
hypoxia core 
condition and 
necrosis and drug 
resistance  
SU3 cell line (glioma) Gelatin-alginate-fibrinogen Extrusion-based [32] 
Hela cell (cervical tumor) Gelatin-alginate-fibrinogen Extrusion-based [31] 
BT474 cell line (breast cancer) 
Poly(ethylene glycol) diacrylate (MW 
700) 
CIJ [30] 
MCF-7 cell line (breast cancer) 
Gelatin - PEG-dimethacrylate (MW 
1000) 
PAM [29] 
 MDA-MB-231 in the center (breast 
cancer) and CAF cells (IMR-90) at the 
edges 
Gelatin-alginate PAM [33] 
Cell-cell 
communication, 
migration, adhesion 
To imitate the 
physiological 
environment and 
show regulatory 
pathways involved 
in migration, 
adhesion processes 
and metastasis 
  
Murine RAW 264.7 Macrophages in the 
core and MDA-MB-231 in the center 
(breast cancer)  
Peptide conjugated alginate fibers Extrusion-based [35] 
MDA-MB-231 cell line (breast cancer)- 
Human fetal osteoblasts 
PEG (MW 300)-PEG diacrylate (MW 
700)-Hydroxyapatite nanoparticles 
Laser-based [37] 
OVCAR-5 cell line (ovarian cancer) – 
MRC-5 cell line (normal human 
fibroblast) 
MatrigelTM (gelatinous protein mixture 
secreted by Engelbreth-Holm-Swarm 
mouse sarcoma cells) 
PAM [36] 
BrCa cell line (breast cancer) cocultured 
with bone stromal cells (fetal osteoblasts 
or bone marrow mesenchymal stem cells)  
Gelatin methacyrlate hydrogel with 
nanocyrstalline hydroxyapatite 
Laser-based [38] 
20 
 
Table 2.  3D printing of personalised cancer treatments. 
 
 
Type of 
personalised 
treatment 
Objectives 
Printing 
method 
Features Results REF. 
Hydrogels for 
controlled drug 
release 
Controlled release hydrogels 
for the treatment of adjunct 
ovarian cancer 
Extrusion-
based 
Poloxamer-based hydrogels with a solid-disk shape 
(12 x 1 mm) containing paclitaxel and rapamycin. 
Drug release controlled over 24 h.  Tumor 
burden decreased from 100 to 30% one day 
post-surgery. Mean survival increased from 20 
to 30 days. 
[45] 
Self-assembling 
thermoresponsive 
nanoemulsions into 
hierarchical mesostructured 
hydrogels 
Laser-based 
Thermoresponsive ink consisting of poly(dimethyl 
siloxane) droplets suspended in an aqueous phase 
with a surfactant, sodium dodecyl sulphate, and a 
crosslinker, poly(ethylene glycol) dimethacrylate. 
Control of the hydrogel microstructure due to 
the fast structural recovery of the nanoemulsion 
after large strain rate yielding a long with a 
shear thinning behaviour that allows the ink to 
conform to the build platform of the printer. 
[47] 
Nanogels for eradicating the 
postoperative residual 
glioblastoma 
Laser-based 
Gelatin methacrylamide scaffold incorporating 
DNA nanocomplexes composed of pVSVMP (a 
plasmid DNA encoding matrix protein of the 
vesicular stomatitis virus), Pluronic F-127 and 
degradable heparin-polyehterimide nanogel 
particles. 
Insertion of the nanogels into the glioblastoma 
resection cavity delayed tumor recurrence and 
significantly prolonged the overall survival in 
mice. 
[50] 
Therapeutic 
implants 
Titanium implants loaded with  
doxorubicin and apoptosis-
inducing ligand for the 
treatment of bone cancer  
Selective 
fusion laser  
The 3D-printed wafer (1.5 × 1.5 cm2) was 
electrochemically anodized to generate an anodic 
layer featuring unique microparticles and 
nanosurface topography to enhance biointegration. 
Doxorubicin and apoptosis-inducing ligand were 
loaded at 188 and 25 µg/cm2 respectively. 
Burst release within 6 h followed by a slow 
release phase of 16 days for doxorubicin and 4 
days for the apoptosis-inducing ligand.  Strong 
in vitro anticancer efficacy against cancer cells. 
[54] 
Implantable anticancer 
magnetocaloric 
polycaprolactone (PCL)/ 
Fe3O4 nanoparticulated mats 
E-jet printing 
A 7% (w/v) solution of PCL in solvents (DMF and 
DCM) was mixed with Fe3O4 magnetic starch 
nanoparticles producing composite solutions that 
were E-jet printed resulting in PCL/Fe3O4 mats. 
Significantly tumor growth inhibition and 
prolongation of survival time of tumor bearing 
mice after 4 weeks of treatment based on the 
application of external alternating magnetic 
fields over 45 min every other day. 
[56] 
Models for 
breast 
reconstruction 
Aesthetically improve breast 
reconstructions 
Extrusion-
based 
3D Fuse deposition modeling printers combined 
with 3D scanners  
Facilitates surgeon’s work when designing a 
breast for a specific patient with its form and its 
own projection, from a flap. 
[62] 
